

22 September 2025

Press Release

KOLAIDO AND PATHWAYS PRECLINICAL PARTNERS LAUNCH STRATEGIC PARTNERSHIP TO DRIVE JOINT GROWTH OF IKOSA IN BIOPHARMA

Combining global scientific consulting with AI-driven bioimaging innovation to scale impact in biotech and biopharma

Altenrhein, Switzerland and Newark, Delaware, United States - Swiss software company KOLAIDO GmbH and Pathways Preclinical Partners, Inc. (Path2P), a U.S.-based consultancy specializing in preclinical, regulatory, and commercialization strategy announce a strategic partnership. This collaboration is designed to harness IKOSA's AI-powered microscopy image analysis capabilities and Pathways' deep scientific and regulatory expertise to catalyze growth across the biotechnology and biopharmaceutical sectors.

Shared Vision & Complementary Strengths

KOLAIDO and Path2P are aligning around a shared philosophy of collaboration and innovation. As KOLAIDO continues to refine and innovate IKOSA's intuitive,

research-oriented platform, it values how Path2P approaches industry partnerships: not just by advising, but by walking alongside clients, sharing the workload, and helping clear the path forward in the biotech and biopharma space.

Together, they aim to offer clients a seamless combination of advanced image analysis tools and strategic development support.

Philipp Kainz, CEO and Co-founder of KOLAIDO, explains, “By joining forces with Path2P, we are not just extending reach, we’re creating a synergy where innovative AI tools and regulatory-scientific guidance elevate each other. This partnership allows us to accelerate IKOSA’s impact in real-world applications.”

Jae Sly, Chairman & CEO of Path2P, adds, “Partnering with KOLAIDO empowers us to deliver game-changing AI image analysis solutions within the context of regulatory and preclinical excellence. We are excited to bring technology to our clients that provides versatility and enhanced capabilities for high-quality imaging without the need to purchase costly microscopes. Just as importantly, IKOSA AI saves our clients time and improves the quality of their data analysis, supporting our goal to accelerate the path to patients.”

With a team of over 35 specialists, including former FDA officials, regulatory strategists, and scientific advisors, Path2P delivers tailored preclinical programs, global clinical strategies, IP planning, and execution support across U.S., EU, and Asian markets. This geographic and functional breadth perfectly complements IKOSA’s potential to serve diverse labs and institutions globally.

IKOSA: AI-Enhanced Bioimaging Across Applications

IKOSA embodies versatility and real-world functionality. The platform enables scientists to build custom AI workflows using IKOSA AI, a no-code development environment with robust reporting and visualization tools. The IKOSA Prisma suite includes optimized analysis modules such as CAM Assay and Cell Painting for angiogenesis studies and high-content profiling. Underpinning it all, the IKOSA Portal supports collaborative team workflows, multi-modal imaging formats, AI-assisted ROI and annotation tools, and seamless integration.

The platform’s adaptability is evidenced across numerous scientific domains - from oncology and neurology to cardiovascular and cellular profiling - utilizing fluorescence, brightfield, time-lapse, and even electron microscopy. These real-world use cases highlight IKOSA’s efficiency and reproducibility advantages.



Introducing Both Collaboration Partners

About KOLAIDO

KOLAIDO develops and operates award-winning microscopy image analysis solutions for the needs of life science research. Powered by the latest Artificial Intelligence technology, their flagship software product, the IKOSA Platform, empowers customers to create their own unique bioimage analysis applications without requiring writing any software code. IKOSA solutions deliver quick, reliable, and reproducible insights into complex life science questions, while supporting more efficiency, flexibility, and precision in research.

Tags: #KOLAIDO #IKOSA #bioimageanalysis #aimicroscopy #digitalmicroscopy

About Pathways Preclinical Partners

Pathways Preclinical Partners (Path2P) provides expert consulting and hands-on support to guide life sciences innovators from preclinical development to clinical trials. Leveraging deep expertise in preclinical and regulatory strategy, CMC development, and product commercialization, Path2P empowers their clients to streamline IND-enabling activities, avoid costly delays, and advance therapies with confidence. Through their global network of investors, CROs, CDMOs, and clinical logistics depots, Path2P delivers flexible, reliable, and strategic solutions that reduce risk and accelerate the path to patients.

Tags: #Path2P #PathtoPatients #DrugDevelopment #PreclinicaltoClinical #BiopharmaConsulting #GlobalPartnerships



Press contact, interview requests, and media

KOLAIDO GmbH

Flughafenstrasse 11

9423 Altenrhein, Switzerland

Tel.: +41 76 697 60 87

E-Mail: press@kolaido.com

Website: <https://www.kolaido.com>

Pathways Preclinical Partners, Inc.

591 Collaboration Way, STE 613

Newark, DE 19713, United States

Tel.: +1 (667) 400-6016

E-Mail: info@path2p.com

Website: <https://www.path2p.com>